Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis E Vaccine Safety and Immunogenicity in Liver Transplant Recipients
ChiCTR2500101910Phase 4Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- May 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of HEV 239 in hepatitis E (HEV), sponsored by Beijing YouAn Hospital. Primary endpoint: Response rate of subjects after hepatitis E vaccination. Planned start May 2025; status: not yet recruiting.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on ChiCTR2500101910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101910.